Janssen Pharmaceutical K.K.

janssen.com

Total trials

127

Active

5

Phase 3

45

Total enrollment

14,498

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 6 of 6 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
JNJ-772421132
AAV5-hRKp.RPGR1
Teclistamab1
GnRH Agonist1
Apalutamide2
Erdafitinib Intravesical Delivery System1

Next readouts

  • 2021-06-09
  • 2025-01-14
  • 2025-03-11
  • 2026-04-22
  • 2027-06-30

Top conditions

  • Healthy26
  • Multiple Myeloma10
  • Schizophrenia9
  • Pain7
  • Hepatitis C, Chronic6
  • Chronic Pain4
  • Alzheimer's Disease4
  • Psoriasis3

Frequently asked questions about Janssen Pharmaceutical K.K.

How many clinical trials does Janssen Pharmaceutical K.K. have on ClinicalTrials.gov?
Janssen Pharmaceutical K.K. is listed as the lead sponsor on 127 clinical trials in ClinicalTrials.gov, 5 of which are currently active (recruiting, enrolling, or ongoing).
How many of Janssen Pharmaceutical K.K.'s trials are in Phase 3?
45 of Janssen Pharmaceutical K.K.'s trials are in Phase 3, spread across 6 active drug programs.
What therapeutic areas does Janssen Pharmaceutical K.K. focus on?
Janssen Pharmaceutical K.K.'s most-studied conditions on ClinicalTrials.gov are Healthy, Multiple Myeloma, Schizophrenia, Pain, Hepatitis C, Chronic.
When are Janssen Pharmaceutical K.K.'s next clinical trial readouts?
Janssen Pharmaceutical K.K. has 5 upcoming primary-completion readouts tracked here; the soonest is “A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma”, expected around 2021-06-09.